Sipuleucel-T: In metastatic castration-resistant prostate cancer

Drugs

Volumn 71, Issue 1, 2011, Pages 101-108

  Plosker, Greg L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

DIPHENHYDRAMINE; DOCETAXEL; PARACETAMOL; PLACEBO; PROVENGE;

ARTHRALGIA; ARTICLE; BACKACHE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; CHILL; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; FATIGUE; FEVER; FOLLOW UP; HEADACHE; HUMAN; HYPERTENSION; METASTASIS; NAUSEA; ORAL PARESTHESIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PARESTHESIA; PHARMACODYNAMICS; PROSTATE CANCER; RESPIRATORY TRACT DISEASE; RISK REDUCTION; SURVIVAL RATE; TACHYCARDIA; TREATMENT INDICATION; VOMITING;

CANCER VACCINES; DISEASE PROGRESSION; HUMANS; MALE; NEOPLASM METASTASIS; ORCHIECTOMY; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TISSUE EXTRACTS;

EID: 78650801857     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11206840-000000000-00000     Document Type: Article

References (25)

1. American Cancer Society. Prostate cancer: what are the key statistics about prostate cancer? [online]. Available from URL: http://www.cancer.org/ Cancer/ProstateCancer/De tailedGuide/prostate-cancer-key-statistics [Accessed 2010 Oct 12].
2. Jemal A, Sigel R, Ward E, et al. Cancer statistics 2009. CA Cancer J Clin 2009; 59: 225-49.
3. American Cancer Society. Prostate cancer: what are the risk factors for prostate cancer? [online]. Available from URL: http://www.cancer.org/Cancer/ ProstateCancer/Detailed Guide/prostate-cancer-risk-factors [Accessed 2010 Oct 12].
4. American Cancer Society. Prostate cancer: 5-year relative survival rates by stage [online]. Available from URL: http://www.cancer.org/Cancer/ ProstateCancer/Detailed Guide/prostate-cancer-survival-rates [Accessed 2010 Oct 12].
5. Walsh PC, DeWeese TL, Eisenberger MA. Clinical practice: localized prostate cancer. N Engl J Med 2007 Dec 27; 357 (26): 2696-705.
6. Carter HB, Kettermann A, Warlick C, et al. Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience. J Urol 2007 Dec; 178 (6): 2359-64.
7. American Cancer Society. Prostate cancer: initial treatment of prostate cancer by stage [online]. Available from URL: http://www.cancer.org/Cancer/ ProstateCancer/Detailed Guide/prostate-cancer-treating-by-stage [Accessed 2010 Oct 12].
8. Di Lorenzo G, Buonerba C, Autorino R, et al. Castration-resistant prostate cancer: current and emerging treatment strategies. Drugs 2010 May 28; 70 (8): 983-1000.
9. Drake CG. Prostate cancer as a model for tumour imm-unotherapy. Nat Rev Immunol 2010 Aug; 10 (8): 580-93.
10. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004 Oct 7; 351 (15): 1513-20.
11. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004 Oct 7; 351 (15): 1502-12.
12. Sheikh NA, Jones LA. CD54 is a surrogate marker of anti-gen presenting cell activation. Cancer Immunol Immuno-ther 2008 Sep; 57 (9): 1381-90.
13. Sipuleucel-T (Provenge®) US prescribing information. Seattle (WA): Dendreon Corporation, 2010.
14. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363 (5): 411-22.
15. Sheikh NA, Rosa CPd, Kuan L-Y, et al. Sipuleucel-T gen-erates robust and persistent cellular and humoral immune responses: results from the IMPACT trial [abstract no. 2932]. 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC.
16. Small EJ, Schellhammer PF, Higano CS, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006 Jul 1; 24 (19): 3089-94.
17. Stewart FP, Rosa CPd, Sheikh NA, et al. Correlation be-tween product parameters and overall survival in three trials of sipuleucel-T, an autologous active cellular imm-unotherapy for the treatment of prostate cancer [abstract no. 4552]. 46th Annual Meeting of the American Society of Clinical Oncology; 2010 Jun 4-8; Chicago (IL).
18. Sheikh NA, Rosa CPd, Frohlich MW, et al. Sipuleucel-T treatment results in sequential ex vivo activation of APCs and T cells during the culture step: evidence for in vivo immunological priming [abstract no. 5608]. 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC.
19. Higano CS, Schellhammer PF, Small EJ, et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipu-leucel-T in advanced prostate cancer. Cancer 2009 Aug 15; 115 (16): 3670-9.
20. Higano CS, Small EJ, Schellhammer PF, et al. Predictors of outcome and subgroup results from the integrated analysis of sipuleucel-T trials in metastatic castration-resistant prostate cancer [abstract no. 4550]. 46th Annual Meeting of the American Society of Clinical Oncology; 2010 Jun 4-8; Chicago (IL).
21. Petrylak DP, Dawson NA, Gardner T, et al. Persistence of immunotherapy survival effects of sipuleucel-T and relationship to postrandomization docetaxel use in phase III studies [abstract no. 4551]. 46th Annual Meeting of the American Society of Clinical Oncology; 2010 Jun 4-8; Chicago (IL).
22. Kantoff P, Higano CS, Berger ER, et al. Updated survival results of the IMPACT trial of sipuleucel-T for metastatic castration-resistant prostate cancer (CRPC) [abstract no. 8]. 2010 Genitourinary Cancers Symposium; 2010 Mar 5-7; San Francisco (CA).
23. Hall SJ, Schellhammer PF, Higano CS, et al. Integrated safety results from four randomized, double-blind, placebo-controlled studies of sipuleucel-T [abstract no. 674]. J Urol 2010 May 31; 183 (4): e263.
24. Fitzhugh M. Medicare committee supports Dendreon's Provenge in controversial review [online]. Available from URL: http://seekingalpha.com/ article/237525-medicare-committee-supports-dendreons-provenge-in-controversial- review [Accessed 2010 Dec 2].
25. Higano CS, Small EJ, Schellhammer P, et al. Sipuleucel-T. Nat Rev Drug Discov 2010 Jul; 9 (7): 513-4